Trial site
Holston Medical Group.
Kingsport, Tennessee 37660, United StatesNot linked to an institution yet
- 14running trials
- 15closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 324 trials
- Phase 25 trials
- Status
- Completed15 trials
- Active, not recruiting9 trials
- Not yet recruiting4 trials
- Recruiting1 trial
- Lead sponsor
- Novo Nordisk A/S21 trials
- Pfizer2 trials
- Applied Therapeutics, Inc.1 trial
- Janssen Research & Development, LLC1 trial
- Kardigan, Inc.1 trial
- and 3 more
Running trials
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021· Phase 2· Novo Nordisk A/S· Source
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· Phase 3· Novo Nordisk A/S· Source
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242· Phase 3· Pfizer· Source
Active, not recruiting
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339· Phase 3· Applied Therapeutics, Inc.· Source
Active, not recruiting
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561· Phase 3· Novo Nordisk A/S· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
NCT06864104· Phase 2· Kardigan, Inc.· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323161· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06323174· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
NCT06269107· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
NCT05844423· Phase 2· Vaxcyte, Inc.· Source
Completed
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05394519· Phase 3· Novo Nordisk A/S· Source
Completed
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522· Phase 3· Pfizer· Source
Completed
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
NCT05486065· Phase 2· Novo Nordisk A/S· Source
Completed
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326· Phase 3· Novo Nordisk A/S· Source
Report an error